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1918Objectives: Acute kidney injury requiring renal replacement therapy (RRT) is a common complication after
cardiac surgery, complicated by suspected or proven heparin-induced thrombocytopenia (type II). The present
study evaluated the use of argatroban as an anticoagulant during continuous RRT in the early period after cardiac
surgery. Argatroban was compared with unfractionated heparin (UH) with respect to bleeding complications and
the effectiveness of anticoagulation.
Methods: Patients requiring RRT after cardiac surgery from March 2007 to June 2009 were identified.
The effectiveness of anticoagulation was measured indirectly by the duration of dialysis filter use. Bleeding
was defined as clinical signs of blood loss or the need for transfusion.
Results: Of 94 patients, 41 received argatroban, 27 UH, and 26 required conversion from UH to argatroban.
In all 3 subgroups, RRT was begun within a median postoperative period of 2.0 days. Similar levels of
anticoagulation were achieved with the duration of the circuit and filter changed an average of 1.1 times daily
during RRT. Liver function was comparable in all patients. Neither clinically relevant signs of bleeding nor
significant differences in the hemoglobin levels or a requirement for transfusion were noted. However, the
Simplified Acute Physiology Score II values during dialysis and mortality were significantly greater in the
patients initially receiving argatroban compared with those who received UH alone (54  2 vs 43  3,
P<.001; 71% vs 44%, P ¼ .04).
Conclusions: Argatroban can provide effective anticoagulation in postoperative cardiac patients receiving
continuous RRT. Close monitoring and dose titration resulted in a comparable risk of bleeding for
anticoagulation with both argatroban and heparin, regardless of the disease severity or impaired hepatic
function. (J Thorac Cardiovasc Surg 2014;147:1918-24)Acute kidney injury (AKI) is a common complication
after cardiac surgery. Depending on the definition of AKI,
the incidence has varied from 0.3% to 29.7%, with a
need for renal replacement therapy (RRT) occurring in
approximately 5% of cases.1-3
Unfractionated heparin (UH) has remained the anti-
coagulant of choice during RRT, because it is inexpensive,
ubiquitously available, simple to dose and monitor, and has
a known antidote in cases of bleeding.4 However, heparin is
contraindicated in certain situations, in particular, if
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The Journal of Thoracic and Cardiovascular Suris suspected or proved. HIT is an important and increasingly
recognized antibody-mediated complication of heparin
therapy occurring in approximately 0.5% to 5% of patients
receiving heparin for5 days.5 Patients undergoing cardiac
surgery are at particular risk. Everett and colleagues6 re-
ported that the postoperative prevalence of heparin/platelet
factor 4 antibodies was as great as 22.4% and that
thromboembolic events occurred in 8.8% of patients
with negative antibodies. This requires an alternative
method of anticoagulation (eg, argatroban).7,8 Argatroban
is a synthetic direct thrombin inhibitor derived from
L-arginine,9 with elimination principally via the hepatic
system,10 avoiding dose adjustment concerns in patients
with renal insufficiency. Furthermore, the development of
antibodies or cross-reactivity resulting in HIT II has not
been described during argatroban therapy.11 Concerns exist,
however, regarding the critically ill, in particular those with
hepatic insufficiency in whom the half-life for elimination
is increased, rendering monitoring and dose adjustment
difficult.8,12 This could increase the potential risk of
severe bleeding complications.
In critically ill patients with AKI requiring RRT, the risk
of bleeding complications within the early postoperative
period increases owing to the anticoagulation required togery c June 2014
Abbreviations and Acronyms
AKI ¼ acute kidney injury
HIT ¼ heparin-induced thrombocytopenia
HIT II ¼ HIT type II
RRT ¼ renal replacement therapy
SAPS ¼ Simplified Acute Physiology Score
UH ¼ unfractionated heparin
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Moreover, in cases of continuous RRT, anticoagulant
accumulation can occur over time. Data on the use of
argatroban within this specific patient population are
sparse.13-15 The aim of the present study was to evaluate
the use of argatroban as an anticoagulant during
continuous RRT for critically ill patients with AKI
requiring RRT during the early period after cardiac
surgery and compare it with the standard practice
anticoagulation using heparin.
METHODS
Patients
All cases of RRT performed from March 2007 to June 2009 within an
intensive care setting at the University Hospital of Saarland were
retrospectively analyzed. The institutional review board (ethical committee
of the Saarland, Germany, 233/11) approved the present study.
Within the study period, 104 patients required RRT in intensive care unit
after cardiac surgery. Ten patients were excluded from the analysis because
their anticoagulation regimen for continuous RRT required conversion on
several occasions from heparin to argatroban or citrate. Data were collected
by retrospective medical chart review for all patients undergoing
continuous RRT. RRT was initiated in cases of AKI with blood urea
nitrogen levels>100 mg/dL or complications such as volume overload
or hyperkalemia became life-threatening and could not be corrected by
conservative treatment. Postoperative AKI was defined on the basis of
the Acute Kidney Injury Network criteria.16 All patients received
continuous venovenous hemodialysis with titration of either UH or
argatroban for anticoagulation. Argatroban was given in cases of proven
or clinically suspected HIT II.17 Clinical suspicion of HITwas determined
by a persistently low or rapid decline in the platelet count or evidence of
thrombosis or embolism as suggested by Lo and colleagues.18
Study Groups
Three subgroups were defined: group 1, patients receiving argatroban
(n ¼ 41); group 2, patients receiving heparin throughout the entire
observation period (n ¼ 27); and group 3, patients requiring conversion
from UH to argatroban (n ¼ 26). Conversion to argatroban was in line
with current recommendations suggesting lower dose argatroban for
critically ill patients, in particular patients with impaired hepatic
function or after cardiac surgery.8,15,19 The initial argatroban dose was
0.25 mg/kg/min. The subsequent dosage was titrated according to the
activated partial thromboplastin time (60-90 seconds) measured within
the extracorporeal circuit. Similarly, anticoagulation with UH was
achieved by an initial bolus and subsequent continuous infusion to
maintain the activated partial thromboplastin time at 60 to 90 seconds.
Treatment and Measurements
The effectiveness of anticoagulation was measured indirectly by the
duration of dialysis filter use. Because the filters were changed routinelyThe Journal of Thoracic and Carevery 24 hours, the requirement for>1 filter daily indicated ineffective
anticoagulation resulting in filter clotting.
Bleeding during anticoagulant therapy was defined as clinical bleeding
signs (eg, postoperative wound bleeding or an increased postoperative
drain volume) or the need for transfusion. The need for transfusion of
erythrocytes was defined by hemoglobin < 9.5 g/dL, independent of
the presence of signs of bleeding. Total erythrocyte transfusion
requirements during the postoperative dialysis period in intensive care
were measured and divided by the days of RRT, described as the
erythrocyte concentrate/day of RRT. The need for platelet transfusion
was defined as thrombocytopenia< 20,000/mL without active bleeding
or < 50,000/mL with signs of active bleeding. The total number of
platelet transfusions during the dialysis period in intensive care was
measured and divided by the days of RRT, depicted as the number
of platelet transfusions/day of RRT. Additional parameters considered
included morbidity (Simplified Acute Physiology Score [SAPS] II)
and outcomes (length of intensive care and hospital stay, duration of
artificial ventilation, and mortality). The biochemical values were
obtained from routine blood samples analyzed within an onsite clinical
laboratory.
Statistical Analysis
All data are presented as the mean  standard error of the mean. Data
analysis was performed using SPSS Statistics, version 19 (IBM, Ehningen,
Germany). An initial comparison between the groups regarding the
dichotomous variables was performed using chi-square tests. Student
t tests were performed for continuous variables to compare the differences
among the groups (Welch’s t tests in the case of inhomogeneous variances).
Two-sided P values were computed.
RESULTS
Patients
Of the 94 patients, 41 (43.6%) received argatroban, 27
(28.7%) received UH, and 26 (27.7%) were converted
from UH to argatroban. In all 3 subgroups, dialysis was
begun within a median postoperative period of 2.0 days.
At the initiation of RRT, no significant differences were
noted in the distribution of gender, age, EuroSCORE II,
or SAPS II scores (Table 1) among the 3 groups.
Biochemical Markers at Initiation of Hemodialysis
The values for biochemical markers obtained at
admission and at the initiation of RRT did not differ
significantly between the argatroban and UH groups,
inclusive of platelet count, markers of renal function
(serum urea or creatinine), and markers of hepatic function
(bilirubin, cholinesterase, and albumin; Table 1). When
RRT was started postoperatively, the hemoglobin level
was comparable but significantly greater statistically in
the patients treatedwith argatroban (10.8 g/dL) than in those
receiving UH (10.1 g/dL) exclusively. Overall, 3 patients
had pre-existing liver disease (2 with Child A, 1 with Child
B). None of these 3 patients had received argatroban.
Results During Hemodialysis
Comparing anticoagulation with argatroban and UH, no
significant differences in hemoglobin levels were noted
during the first 3 days of RRT (Figure 1). Furthermore,diovascular Surgery c Volume 147, Number 6 1919
TABLE 1. Basic characteristics
Characteristic
Argatroban
(group 1; n ¼ 41)
Heparin
(group 2; n ¼ 27)
P value
(group 1 vs 2)
Heparin to argatroban
(group 3; n ¼ 26)
P value
Group 1 vs 3 Group 2 vs 3
Before surgery
Male gender (n) 34 (83) 18 (67) .15 14 (54) .01* .41
Age (y) 74  9 70  10 .10 73  10 .15 .85
Weight (kg) 83  3 77  3 .13 78  3 .21 .84
Size (cm) 170  1 170  1 .76 167  2 .15 .09
EuroSCORE 10.8  0.7 9.3  0.8 .18 10.8  0.7 .96 .013
NYHA class 3.0  0.1 3.2  0.1 .23 3.1  0.1 .68 .44
Hemoglobin (g/dL) 12.9  0.3 12.2  0.3 .14 12.5  0.3 .047 .51
Creatinine (mg/dL) 1.7  0.1 2.1  0.4 .27 2.1  0.4 .19 .95
Urea (mg/dL) 75  7 75  11 .96 66  6 .32 .47
INR 1.2  0.1 1.1  0.1 .51 1.1  0.1 .49 .93
Bilirubin 0.7  0.1 1.4  0.4 .10 0.9  0.1 .15 .21
Comorbidity
Atrial fibrillation 15 (37) 6 (22) .29 1 (4) .03* .10
Arterial hypertension 38 (93) 20 (74) .08 23 (89) .67 .29
Coronary artery disease 31 (76) 17 (63) .29 16 (62) .28 1
Pulmonary hypertension 9 (22) 7 (26) .77 14 (54) .01* .05
Status after stroke 5 (12) 0 (0) .15 6 (23) .32 .01*
Diabetes 12 (29) 7 (26) 1 9 (35) .79 .56
Liver disease 0 (0) 3 (11) .06 0 (0) 1 .24
Intraoperative
Procedure type
Emergent or urgent 3 (7) 0 (0) .27 1 (4) 1 .49
CABG 24 (59) 17 (63) .80 15 (58) 1 .78
Valve operation 23 (56) 13 (48) .62 19 (73) .2 .09
Combination surgery 14 (34) 7 (26) .59 14 (54) .13 .05
Redo CABG and/or valve 11 (27) 4 (15) .37 5 (19) .57 .73
Operation time (min) 220  11 227  17 .70 214  17 .75 .57
CPB time (min) 112  8 106  11 .66 117  14 .70 .53
AXC time (min) 56  3 62  5 .34 59  6 .71 .70
IABP 8 (20) 4 (15) .75 5 (19) 1 .73
Before hemodialysis
SAPS II 44  2 41  3 .43 44  2 .90 .49
Laboratory markers
Hemoglobin (g/dL) 10.8  0.2 10.1  0.2 .03* 10.2  0.2 .07 .61
Blood platelets (n) 106  12 118  14 .53 84  12 .21 .07
Creatinine (mg/dL) 3.2  0.2 3.1  0.3 .87 2.6  0.3 .15 .30
Urea (mg/dL) 120  9 108  11 .43 82  8 .004* .06
Calcium (mmol/L) 2.2  0.1 2.2  0.1 .92 2.3  0.1 .11 .06
Bilirubin 2.9  0.3 3.2  0.9 .15 1.5  0.2 .17 .05
Cholinesterase (kU/L) 2.9  0.1 3.6  0.4 .09 3.5  0.3 .04* .84
Albumin (g/L) 23  1 26  1 .02* 25  1 .28 .26
Outcome
Maximum SAPS II 54  2 43  3 <.001* 55  2 .78 <.001*
Mechanical ventilation (h) 276  35 239  57 .56 348  65 .29 .21
LOS ICU (d) 11  1 8  2 .16 16  4 .16 .07
LOS hospital (d) 19  2 28  4 .04* 29  5 .05 .87
30-d mortality 29 (71) 12 (44) .04* 14 (54) .20 .59
Total sets (n) 7  1 4  1 <.001* 11  2 .007* <.001*
Sets/day of dialysis (n) 1.1  0.1 1.1  0.1 .56 1.1  0.1 .35 .33
Data presented as mean  standard deviation or n (%). NYHA, New York Heart Association; INR, international normalized ratio; CABG, coronary artery bypass grafting;
CPB, cardiopulmonary bypass; AXC, aortic crossclamp; IABP, intra-aortic balloon pump; SAPS, Simplified Acute Physiology Score; LOS, length of stay; ICU, intensive care
unit. *Statistically significant.
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FIGURE 1. Need for transfusion, fluid balance, and hemoglobin within the first 3 days of continuous venovenous hemodialysis in patients receiving
heparin or argatroban.
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Mno significant differences were found in erythrocyte
or platelet transfusion requirements (Figure 1). The fluid
balance at day 1 of RRT was significantly higher in
patients receiving argatroban compared with heparin
(1228  548 vs 957  481; P < .01; Figure 1). No
significant difference was noted during the subsequent
2 days of RRT.
Anticoagulation with argatroban compared with UH and
conversion from UH to argatroban during RRT resulted in
no significant difference in hemoglobin levels (Figure 2).
No significant differences in the erythrocyte concentrate
or platelet transfusion requirements were noted among the
3 groups during the observation period (Figure 2). However,
the duration of dialysis was significantly longer in patients
receiving argatroban and in those converted from UH to
argatroban compared with those receiving UH alone
(6.5  0.7 and 10.1  1.3 vs 3.2  0.5; P < .001;
Figure 2). Transfusion requirements per day with
erythrocytes or platelets before and after conversion from
UH to argatroban in group 3 were comparable (Table 2).
Similar levels of anticoagulation were achieved among all
3 groups, with the dialysis circuit and filter changed an
average of 1.1 times per day of RRT (Table 1).Outcome Parameters
The maximal SAPS II scores during dialysis were
significantly elevated in group 1 (argatroban) and group 3The Journal of Thoracic and Car(conversion from UH to argatroban) compared with group
2 (UH; 54  2 and 55  2 vs 43  3; P<.001; Table 1).
Patients receiving argatroban had higher levels of mortality
than patients receiving UH alone. However, this was only
statistically significant for patients starting with
argatroban (44% vs 71%). No mortalities secondary to
bleeding complications occurred. The differences in
mechanical ventilation, length of intensive care or hospital
stay, and 30-day mortality were not statistically significant
(Table 1) among all 3 groups.DISCUSSION
The choice of postoperative anticoagulation for patients
with AKI requiring RRT has been difficult owing to the
significant risk of bleeding. It has been proposed that this
risk might be greater with argatroban than with UH, with
impaired hepatic function in critically ill patients
potentially prolonging the half-life of argatroban.8,15 The
absence of a readily available antidote adds additional
concern. The present retrospective study investigated
whether the risk of bleeding complications in patients
with AKI requiring RRT after cardiac surgery and
anticoagulated with argatroban is greater than with
anticoagulation using UH.
Previous studies have been published on intermittent
dialysis and argatroban for critically ill patients,14 for the
evaluation of bleeding and thrombotic risk after cardiacdiovascular Surgery c Volume 147, Number 6 1921
FIGURE 2. Need for transfusion daily, duration of dialysis, and hemoglobin during dialysis period in patients receiving argatroban or heparin or whowere
switched from heparin to argatroban.
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for the evaluation of argatroban dosing in patients
with multiple organ dysfunction,8,15 with 31,13 47,17 30,8
and 1215 patients, respectively. Such studies were
limited by small patient numbers and did not directly
compare treatment with argatroban against heparin. The
present study considered 41 postoperative critical care
patients receiving continuous RRT and anticoagulation
with argatroban, making it the largest evaluation of its
kind to date.Choice of Anticoagulation and HIT II
UH is the most commonly used anticoagulant for
continuous RRT.4 In the present study period, UH was
used as the standard form of anticoagulation for RRT at
our center. Although dialysis was started within a median
postoperative period of 2.0 days, in 41 patients, a clinicalTABLE 2. Need for transfusion per day during continuous
venovenous hemodialysis
Transfusion
UH conversion to argatroban
P
value
UH
(n ¼ 26)
Argatroban
(n ¼ 26)
Packed RBC/d (U) 1.2  0.3 1.0  0.1 .32
Packed blood platelets/d (U) 0.3  0.1 0.4  0.1 .62
RBC, Red blood cell; UH, unfractionated heparin.
1922 The Journal of Thoracic and Cardiovascular Sursuspicion of HIT II arose because of a decline in platelets
that could not be explained by the cardiopulmonary bypass
or evidence of thrombosis or embolism, as suggested by Lo
and colleagues.18 Most of these patients had received
heparin-based anticoagulation before surgery, supporting
a clinical suspicion of HIT II. This—at least in
part—explains why dialysis was started with argatroban
in 41 patients, which might otherwise have appeared
excessive.With a clinical suspicion of HIT II and nomethod
of absolutely excluding such a diagnosis, it was thought
safer to avoid anticoagulation with UH postoperatively.
HIT II was confirmed in 7% of patients starting with
argatroban. HIT II was later confirmed in 15% of patients
receiving UH and switched to argatroban.
Anticoagulation with citrate offers a possible alternative
in cases of HIT II. Although the efficacy and safety of
regional citrate anticoagulation has largely been described,
its diffusion appears relatively limited, ranging from about
10% (Beginning and Ending Supportive Therapy for the
Kidney [BEST] study)8 to 20% (Acute Renal Failure Trial
Network study)16 in continuous RRT. In our center, the use
of citrate for anticoagulation during RRT before 2010 was
rather limited owing to initial technical limitations. Thus,
citrate was only used in a few patients with ongoing or se-
vere bleeding complications within the postoperative phase,
where RRT was deemed necessary and the anticoagulation
regimen for RRT was changed on several occasions.gery c June 2014
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Sufficient anticoagulation is essential in dialysis to
minimize coagulation within the extracorporeal circuit.
However, achieving adequate anticoagulation can be
complicated by factors such as HIT, extracorporeal circuit
clotting, and changes in the RRT anticoagulant require-
ments over time. Thus maintaining continuous RRT for
several days is challenging, with anticoagulation moni-
toring and dosage further complicated in treating critically
ill patients with the potential to develop hepatic impairment
or multiorgan failure.
Inadequate anticoagulation within the extracorporeal unit
will result in higher filter requirements.4 A comparison
among the 3 groups showed a mean requirement of
1.1 filters/day of dialysis (Table 1). Close monitoring of
anticoagulation allowed maintenance of the activated
partial thromboplastin time within the desired therapeutic
range of 60 to 90 seconds. This combination of laboratory
monitoring and longevity of the circuit filters between
the groups treated with argatroban indirectly suggested
comparably effective anticoagulation.
Blood Loss
Transfusion rates of 10% to 60% for patients after
cardiac surgery have previously been reported.20,21
Transfusion was undertaken in all patients for whom
hemoglobin was <9.5 g/dL, with the intention of
maintaining hemoglobin at >10 g/dL. Although the
guidelines specify an initial transfusion at lower
hemoglobin levels,22 evidence has also been presented in
support of early transfusion.23
Anticoagulation during RRT can lead to increased blood
loss postoperatively. However, no evidence was observed
clinically within the present study to support this.
Furthermore, the transfusion requirements to maintain
hemoglobin levels at or>10 g/dL during RRT were the
same, indirectly excluding any clinically relevant bleeding.
The hemoglobin values can vary with shifts in fluid volume,
which in the present context need not be associated with
bleeding. By maintaining a comparably consistent volume
balance among the groups, the effect of this factor was
negated. Clotting within the filter and extracorporeal circuit
with subsequent disposal can result in blood loss of around
250 mL. In our evaluation, the requirement for filter
changes remained constant at 1.1/dialysis day. Two conclu-
sions can be inferred from this finding: the anticoagulation
was adequate and thus no difference resulted in blood
loss secondary to the filter changes among the 3 groups.
Furthermore, the changes in hemoglobin levels did not
result from dilution as a consequence of relevant
differences in the fluid balances. The direct influence of
the anticoagulant on patient transfusion requirements could
be seen in those requiring conversion from heparin to
argatroban (Table 1). No statistically significant differenceThe Journal of Thoracic and Carwas noted between argatroban and UH. This was related
to a tendency for reduced postoperative transfusion
requirements over time, rather than problems relating to
the correct anticoagulation dosage.
Bleeding Risk
Comparing the laboratory findings, no significant
difference was observed among the 3 groups. Although
some patients showed signs of hepatic impairment, with
elevated bilirubin and reduced cholinesterases at
dialysis initiation, the incidence of bleeding complications
remained comparable among the 3 groups. Despite the
hepatic dysfunction significantly prolonging the half-life
of argatroban, the incidence of bleeding did not increase.8,26
We appreciate this was likely a result of close monitoring
and dose adjustment, as previously described in published
studies.8,26,27
Some nonsignificant differences by gender (male 83% vs
female 54%) and age (70 vs 74 years) were noted between
the 2 groups, with the argatroban group on average older
than the UH group. In agreement with the few previous
publications in this field, we found no association between
patient age and the risk of bleeding with argatroban.27
Although the severity of disease (SAPS II) at the start of
RRT was not statistically significant, patients exclusively
receiving argatroban or converted to argatroban from UH
tended to start dialysis with a higher SAPS II score. During
the dialysis period, the maximal SAPS II score increased in
these 2 groups from 44 to 54 and 55, but remained almost
unchanged in the UH-only group (SAPS II, 41 or 43).
Despite the increasing disease severity, no bleeding
complications developed. We attributed this to the rapid
adjustment of the argatroban dosage, as described in other
studies.8,13,15
Outcome and Mortality
The outcome and mortality in our study was comparable
to that of other studies, because the postoperative morbidity
and mortality has been significantly greater in patients who
develop AKI after cardiac surgery.2,28,29
Patients receiving UH had a longer overall inpatient stay,
despite a reduced intensive care stay (8 vs 11 days) and dial-
ysis requirements, potentially accounted for by differences
in morbidity and outcome. A higher SAPS II score was
equated with greater mortality and thus a shorter length of
stay. The patients initially receiving argatroban had a higher
maximal SAPS II score and mortality than those receiving
UH alone (44% vs 71%). We assumed that this could
account for the observed differences in fluid balance. An
association between a positive fluid balance and greater
mortality has been supported by several studies.24,25
Furthermore, by having a higher maximal SAPS II score,
factors such as patient age at baseline, a known
confounding variable in postoperative mortality afterdiovascular Surgery c Volume 147, Number 6 1923
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developing postoperative complications. No mortality
secondary to bleeding complications was observed. Thus,
the outcomes and mortality were less associated with
mode of anticoagulation during RRT than with age or
disease severity.Study Limitations
The significance of the study results was limited by the
comparatively small group sizes. Furthermore, variations
in the baseline cardiac pathology and the intraoperative
procedure undertaken complicated the standardization,
even if no statistically significant difference was found.
One particular concern was related to the clinical judgment
of bleeding and the basis for transfusion. The rapid
initiation of postoperative RRT can be associated with
dialysis-associated blood loss, creating confusion regarding
whether the blood loss was associated with RRT or
secondary to the surgical insult. This concern can only be
partially resolved by knowing that the median day of
dialysis initiation was the same, irrespective of the
group (day 2) and therefore that effect was comparable,
regardless of the anticoagulant used.CONCLUSIONS
Argatroban can provide effective anticoagulation in
postoperative cardiac patients receiving continuous RRT
within an intensive care setting. Close monitoring and
dose titration results in a comparable risk of bleeding with
anticoagulation using either argatroban or heparin,
regardless of the underlying disease severity or hepatic
impairment.References
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